All In Biotech

Free tool

FAERS Monitor: Voquezna Dual Pak

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215153 or its brand name (Voquezna Dual Pak, Amoxicillin, Vonoprazan Fumarate). Reports on generic versions are filed under their own applications.

Reports

24

Serious

4

17% of reports

Hospitalization

2

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea5
  • drug ineffective4
  • abdominal pain upper3
  • diarrhoea3
  • dizziness3
  • dyspnoea3
  • off label use3
  • oropharyngeal pain3
  • cough2
  • decreased appetite2
  • headache2
  • hospitalisation2
  • illness2
  • influenza like illness2
  • pain2

Reports by year received

View as table
YearReports
20246
20257
202611

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,135 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
oropharyngeal painSignal328.49.955
influenza like illness221.35.621
illness217.04.516
abdominal pain upperSignal312.84.422
hospitalisation211.43.010
decreased appetite27.52.06
cough26.31.74
nauseaSignal55.52.515
dizzinessSignal35.31.87
dyspnoeaSignal34.61.65
diarrhoeaSignal34.11.44
off label use33.01.02
pain22.90.81
headache22.80.71
drug ineffective42.71.13

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.